102.05
Monopar Therapeutics Inc stock is traded at $102.05, with a volume of 89,000.
It is up +16.20% in the last 24 hours and up +107.33% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$87.82
Open:
$90.75
24h Volume:
89,000
Relative Volume:
1.70
Market Cap:
$629.64M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-44.37
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+2.56%
1M Performance:
+107.33%
6M Performance:
+192.49%
1Y Performance:
+1,755%
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MNPR
Monopar Therapeutics Inc
|
102.05 | 541.85M | 0 | -7.12M | -6.82M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-09-25 | Initiated | BTIG Research | Buy |
Sep-03-25 | Initiated | Oppenheimer | Outperform |
Sep-03-25 | Initiated | Raymond James | Strong Buy |
Aug-26-25 | Resumed | H.C. Wainwright | Buy |
Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
Mar-19-25 | Resumed | Piper Sandler | Overweight |
Jan-10-25 | Initiated | Piper Sandler | Overweight |
Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Is Monopar Therapeutics Inc. stock safe for conservative investorsChart Signals & Smart Money Movement Tracker - newser.com
Is Monopar Therapeutics Inc. forming a reversal patternPortfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Multi factor analysis applied to Monopar Therapeutics Inc.2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Will Monopar Therapeutics Inc. stock recover faster than peersJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
MNPR: Barclays Initiates Coverage with Overweight Rating | MNPR Stock News - GuruFocus
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Monopar Therapeutics initiated with an Overweight at Barclays - TipRanks
Real time social sentiment graph for Monopar Therapeutics Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Raised to Strong-Buy at Jones Trading - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 12.3%Here's What Happened - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Upgraded to "Strong-Buy" at Jones Trading - MarketBeat
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR) - Seeking Alpha
Institutional scanner results for Monopar Therapeutics Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Monopar Therapeutics' (MNPR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential - TipRanks
What analysts say about Monopar Therapeutics Inc stockProtective Put Strategies & Low Risk Investment Trading - earlytimes.in
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Raymond James Maintains Monopar Therapeutics (MNPR) Strong Buy Recommendation - Nasdaq
MNPR: Raymond James Raises Price Target to $142, Maintains Stron - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year HighTime to Buy? - MarketBeat
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsWatch List & Fast Gaining Stock Strategy Reports - newser.com
Historical volatility pattern of Monopar Therapeutics Inc. visualizedTrade Entry Summary & Entry Point Strategy Guides - newser.com
Will Monopar Therapeutics Inc. (1IY0) stock beat Nasdaq index returnsTrade Risk Summary & Long-Term Safe Investment Ideas - newser.com
Risk adjusted return profile for Monopar Therapeutics Inc. analyzedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Is Monopar Therapeutics Inc. (1IY0) stock overpriced at current multiplesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsGlobal Markets & Community Shared Stock Ideas - newser.com
Can volume confirm reversal in Monopar Therapeutics Inc.July 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Oppenheimer Maintains Monopar Therapeutics (MNPR) Outperform Recommendation - Nasdaq
Oppenheimer Raises Price Target for Monopar Therapeutics (MNPR) - GuruFocus
Oppenheimer Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $115 - 富途牛牛
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - 富途牛牛
HC Wainwright Has Optimistic Outlook of MNPR FY2027 Earnings - Defense World
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):